



Prof. Dr. Albert D.M.E. Osterhaus, DVM PhD

Date and place of birth: 02.06.1948,
Amsterdam,
The Netherlands
Nationality : Dutch
Address : Centre of
Infection Medicine
and Zoonosis
Research
University of
Veterinary Medicine
Bünteweg 17
30559 Hannover,
Germany

Phone: +49(0)511 953 6140
Email: albert.osterhaus@tiho-hannover.de



Scientific education

- 2001 Educator, specialisation Medical Microbiology, Stichting Medisch Biologisch Wetenschappelijk Onderzoeker (SMBWO)
- 1996 Registered veterinary microbiologist
- 1978 Doctoral Thesis (Ph.D.), University of Utrecht, The Netherlands
Feline Infectious Peritonitis Virus: Identification, Propagation and Epidemiology (promotors: Prof.Dr.M.C.Horzinek, Prof.Dr.J.van Bekkum)
- 1974 Graduated as a veterinarian (with honours)
- 1973 Veterinary doctorate (cum laude)
- 1969 Veterinary candidate (cum laude)
- 1967 - 1974 Faculty of Veterinary Medicine, University of Utrecht,
The Netherlands
- 1961 - 1967 HBS-B Pius X Lyceum, Amsterdam

Previous and present positions

- 2013 - present Guest Professor Tierärztliche Hochschule Hannover, Germany
Head of Department of Viroscience, Erasmus MC, Rotterdam
- 2011 - present Professor of Wildlife Virology and Virus Discovery, University Utrecht
- 2009 - present Chairman Master Infection & Immunity Erasmus MC
Member of the Graduate School Erasmus MC
- 2007 - present Chairman of the Postgraduate School Molecular Medicine Erasmus MC
- 2003 - present Head WHO National Reference Laboratory for Measles and Rubella
icw RIVM
- 1995 - present Director WHO Collaborating Centre for Arboviruses and
Haemorrhagic
Fever Reference and Research
- 1995 - 2000 Director WHO Global Reference Laboratory for Measles, Rotterdam
- 1993 - present Director National Influenza Center (NIC), Rotterdam

| | |
|----------------|---|
| 1993 - 2013 | Head of Department of Virology, Erasmus MC, Rotterdam |
| 1993 - present | Professor of Virology, Erasmus MC, Rotterdam |
| 1990 - 2011 | Professor of Environmental Virology, State University Utrecht |
| 1978 - 1994 | National Institute of Public Health and Environmental Protection (RIVM), Bilthoven, The Netherlands, last position: Head of the Laboratory of Immunobiology |

Synopsis

Professor Osterhaus has been Head of the Department of Viroscience at Erasmus MC Rotterdam until July 1st 2014, is currently Professor of Wildlife Virology and Virus Discovery at Utrecht University, and Director of the Center of Infection Medicine and Zoonosis Research and Guest-Professor at the Tierärztliche Hochschule Hannover. He has a long track record as a scientific researcher and Principal Investigator of numerous major scientific projects.

At Erasmus MC, Professor Osterhaus has run a diagnostic virology lab with more than 40 staff and a research virology lab with over 150 personnel. His research programme follows a novel integrated viroscience concept, bringing together world-leading scientists in molecular virology, immunology, epidemiology, pathogenesis, and intervention studies on human and animal virus infections.

Among the major accomplishments are the discovery of more than 40 new viruses of humans and animals (e.g. human metapneumovirus, coronaviruses, influenza viruses), elucidation of the pathogenesis of major human and animal virus infections, and development of novel intervention strategies. This has enabled health authorities like the WHO to effectively combat disease outbreaks like SARS and avian influenza. The spin-off, Viroclinics Biosciences BV, is another societally relevant success, allowing effective testing and refining of diagnostic tools and other intervention strategies.

The international recognition of Professor Osterhaus is further highlighted by awards, prizes, guest lecture invitations, (co-)organiserships of international meetings and editorships of scientific journals.

Professor Osterhaus has acted as PhD mentor for more than 60 students and holds several key patents. He is also the author of more than 1020 papers in peer-reviewed journals, together cited more than 50,000 times, and his H index is more than 90.

Most of all, Professor Osterhaus firmly believes that scientists have a role to play in translating their knowledge for the benefit and protection of society.

Membership to professional organizations

- American Society for Microbiology
- Society for General Microbiology
- European Wetenschappelijk Werkgroep on Influenza
- European Society for Veterinary Virology
- European Society for Clinical Virology
- European Association for Aquatic Mammals
- International Association for Aquatic Animal Medicine
- Nederlands Society for Microbiology
- Nederlands Society for Laboratory Animal Science
- Nederlands Society for Immunology
- Royal Nederlands Society for Animal Science
- International Society for Vaccines; Executive Commissie Lid
- International Consortium on Anti-virals
- American Society for Virology
- European Society of Tropical Medicine and Hygiene

Editorial appointments

| | |
|----------------|---|
| 2001 | Editor Options for the control of influenza IV , Exerpta Medica, International Congress Series No. 1219, Elsevier Science BV, |
| 1995 - 1999 | Editor "Journal of Medical Primatology" |
| 1995 - 2000 | Editor "Journal of General Virology" |
| 1995 - present | Editor "Adjuvant Research" |
| 1993 - present | European Editor "Vaccine" |
| 1991 - 2001 | Editor "Veterinary Quarterly" |
| 1991 - 2000 | Editor "Tijdschrift voor Diergeneeskunde" |

1990 - present Editor "FEMS Immunology/Microbiology"

1990 Editor "Viral Infections of Vertebrates", Volume "Viral Infections of Rodents and Lagomorphs", Editor in Chief M.C. Horzinek, Elsevier Science Publishers

1989 Editor "Idiotypic Networks in Biology and Medicine", Elsevier Science Publishers, 1990

1987 - present Associate Editor "Viral Immunology"

Amsterdam

2012 - present Editorial Board member Journal of Virology and Microbiology

2010 - present Editorial Board member Platform Infectieziekten

Member Editorial Board Infectious Disease

Co-Editor-in-Chief Current Opinion in Virology

2008 - present Editorial Board member of EMBO Molecular Medicine

2008 - 2014 Editorial Board member Advances in Virology

2008 - present Associate Editor BMC Microbiology

2006 - present Editor Medical Microbiology and Immunology

2005 - present Editor BMC Infectious Diseases

Editorial Board member BMC Microbiology

Editor Medical Microbiology and Immunology

2002 - present Editor Journal of Clinical Virology

Awards

2012 WSAVA Global One Health Award

2010 ESCMID Award for Excellence in Clinical Microbiology and Infectious Diseases

2008 Erasmus Award, Erasmus MC Rotterdam, The Netherlands

2007 Allan Granoff Lectureship in Virology Award, St. Jude's Hospital

Prix scientifique Louis D - Académie des sciences de l'Institut de France - research done in the field of transmissible diseases from man to animals, anthroozoonoses.

2006 European Respiratory Society - European Lung Foundation Award - recognition of the contribution to the public lung health in Europe

Federa prize for original and exceptional research achievements

2004 Reinier de Graaf medal for exceptional contribution to medicine

Dr. Saal van Zwanenberg-Oragon prize for exceptional achievement in promoting scientific research

James H. Nakano Citation - CDC prize for exceptional scientific publications.

2003 Commander in the Order of the Dutch Lion - Royal decoration

2002 The ESCV Gardner Lecture - Viruses emerging from animal reservoirs

2000 Mulder-Masurel Award on influenza research

UK Royal Society invited lecture on Catastrophes after

crossing species barriers

- 1998 M.W.Beijerinck Virology Award, Royal Dutch Academy of Sciences
- 1995 Firkin Oration, Australian Society for Medical Research
- 1993 Laureate Van Loghem lecture, Dutch Society for Immunology
- 1992 Ciba Geigy Prize for Research in Animal Health
- 1989 Heine Medin Award: European Society against Virus Diseases
- 1985 Schimmel Viruly Award: Faculty of Veterinary Medicine, Utrecht

Patents (Selection out of >30)

- 2012 MERS-CoV receptor (pending)
- MERS-CoV (pending)
- 2009 MVA-patent influenza (application)
- 2008 WO2008061939 Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu.
- 2007 US2007087333 Method to detect antigen-specific cytolytic activity, Publication date: 2007-04-19
- 2005 WO 2005/080991 Method to detect antigen-specific cytolytic activity
- 2003 US 2004/0005544 (US Appl. # 10/371.122) Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of heterologous antigenic sequences .
- 2002 WO 2002/057302(# PCT/NL02/00040) A virus causing respiratory tract illness in susceptible mammals
- 01200213.5 Human metapneumovirus national phase application
- 2001 US 2001/631966B1 in cooperation with Aventis Pasteur Induction of rev and tat specific cytotoxic T- cells for prevention and treatment of human immunodeficiency virus (HIV)
- 1996 Patent in samenwerking met Pasteur Mérieux Connaught, betreffende "Induction of rev and tat specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection".
- 1992 Patent in samenwerking met Pitman Moore, betreffende "Deletion cleavage site of the FIV glycoprotein".
- Patent in samenwerking met Pitman Moore, betreffende "Identificatie, virus neutralization determinant of FIV".
- Europees Patent nr. 92202032.6: "Monoclonal antibodies to HIV-1 gp120, cell lines producing them, preparations for passive immunotherapy, vaccines containing corresponding epitope structures and process of preparing these antibodies". (Date of submission: 3 July 1992).

NIH

- 2009 Animal Models of Infectious Diseases
- 2006 SARS
- 2000 Protective capacity of HIV early protein specific CTL

NGI

- 2009 FES 2009, research line viral infections k 1700

| | | | |
|------|--|---|------|
| 2009 | VIRGO II | k | 700 |
| 2004 | VIRGO - Genomics and respiratory viruses | K | 2300 |

WHO

| | | | |
|------|--|---|-----|
| 2002 | Efficacy and Safety of a Tetravalent Dengue Vaccine in a Macaque Model | k | 140 |
| 2001 | Aerosol vaccination against measles | k | 120 |
| 2000 | Novel generations of measles vaccines | k | 100 |

PI / co-investigator Clinical Trials

| | |
|------|--|
| 2012 | PI in an MVA recombinant influenza phase I clinical trial (investigator initiated) |
| 2006 | PI in an autologous DC vaccination study in HIV infected humans (investigator initiated) |
| 2000 | Investigator in: a double blind, randomised, placebo-controlled study of RWJ 270201 for the treatment of influenza infections in asthmatic subjects. |
| 1999 | Investigator in: a double blind, randomised, placebo-controlled study of RWJ 270201 for the treatment of influenza infections in healthy subjects. Investigator in: immunogenicity and tolerability of three dosages of an anti RSV vaccine, administered in an ambulant elderly adult population over 60 years old. |
| 1998 | Principal Investigator in: a single center, single-blinded placebo-controlled study of a recombinant RSV vaccine in the treatment of severe lower respiratory tract infection. Principal Investigator in: a double blind, randomised, placebo-controlled study of Ro 64-0796 (also known as GS 4104) in the treatment of influenza in children with chronic asthma. Principal Investigator in: a double blind, randomised, placebo-controlled study of Ro 64-0796 (also known as GS 4104) used for the treatment of influenza infection. |
| 1997 | Principal Investigator in: a double blind, randomised, placebo-controlled study of Ro 64-0796 (also known as GS 4104) used for the prevention of clinical influenza post exposure. Principal Investigator in: a randomised, double-blind study to determine the cell-mediated and humoral immunogenicity of two influenza ISCOM vaccines (type I and II) versus Fluvax® (inactivated influenza vaccine split virion) in young healthy adults. |
| 1996 | Principal Investigator in: a double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered twice a day for five days in the treatment of symptomatic Influenza A and B viral infections in adolescents and adults. |
| 1995 | Principal Investigator in: a double-blind, randomised, placebo-controlled, multicentre parallel-group study to investigate the efficacy and safety of GG167 administered twice or four times a day for the treatment of Influenza A and B viral infections. |
| 1994 | Principal Investigator in: a double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled and intranasal GG167 in the treatment of Influenza A and B viral infections. Principal Investigator in: GMDP as adjuvant to Influvac subunit vaccine Immunogenicity and reactogenicity of adjuvant GMDP orally administered just prior to vaccination with a trivalent influenza subunit vaccine. A double-blind placebo controlled study in nursing home residents. |

Identification of novel viral pathogens in humans and animals

| | |
|------|---|
| 2014 | Identification of python torovirus |
| 2013 | Identification of human cyclovirus Identification of seal parvovirus Identification of fox HEV |
| 2012 | Identification of coronavirus as primary cause of MERS (MERS-CoV) Identification of boa arenavirus Identification of human calicivirus |
| 2011 | Influenza A (H1N1) virus in dogs Identification of stone marten anellovirus Identification of porcine picobirnavirus Identification of ferret heptatitis E virus (HEV) Identification of ferret coronavirus |
| 2010 | Identification of human picobirnavirus Identification of human astrovirus |
| 2009 | Identification of deer astrovirus |
| 2006 | Identification of dolphin herpesvirus |
| 2005 | Identification of H16 influenza A viruses in black headed gulls |
| 2004 | Identification of fourth human coronavirus |
| 2003 | Identification of influenza A (H7N7) virus in humans Identification of coronavirus as the primary cause of SARS (SARS-CoV) |
| 2002 | Presence of hantavirus infection in Barbados Presence of hantavirus infection in Indonesia Identification of re-emerging PDV in Europe |
| 2000 | Identification of human metapneumovirus (hMPV) as a new member of the genus Metapneumovirus Identification of measles virus re-introduction in The Netherlands |
| 1999 | Identification of influenza B virus in seals |
| 1998 | Identification of a lentivirus from Talapoin monkeys (SIVtal) |
| 1997 | Identification of influenza A (H5N1) virus in humans Identification of monk seal morbilliviruses (MSMV-WA/G) |
| 1996 | Identification of a ?-herpesvirus in seals (phocid herpesvirus-2) |
| 1995 | Identification of CDV as cause of mass mortality in Serengeti lions Hepatitis B virus infection in heart transplant patients in the Dijkzigt Hospital Rotterdam |
| 1994 | Parapoxvirus in grey seals |
| 1992 | Rhabdovirus of dolphins Porpoise and dolphin morbilliviruses causing mortality in cetacean species |

| | |
|------|---|
| 1990 | First Orthopoxvirus in seals (affected by PDV infection) |
| 1989 | First demonstration of Hantavirus infections in humans and rodents in The Netherlands |
| 1988 | First picornavirus in seals (affected by PDV infection) First phocid morbillivirus (phocid distemper virus, PDV): cause of mass mortality in seals |
| 1984 | First phocid herpesvirus (phocid herpesvirus 1): high mortality in young seals |
| 1981 | First demonstration of mouse pox in The Netherlands |
| 1978 | First demonstration of canine parvovirus in The Netherlands |
| 1977 | First non mammalian papillomavirus: Finch papilloma virus |

Sie sind hier: [Kliniken & Institute](#) > [Forschungszentrum für Infektio...](#) > [Research Groups and Management...](#) > [AG Osterhaus](#) > [Project leader](#)

Dieses PDF-Dokument wurde dynamisch auf www.tiho-hannover.de erstellt.

Letzte Aktualisierung dieses Dokumentes: 13. Juli 2018

© Stiftung Tierärztliche Hochschule Hannover, Bünteweg 2, 30559 Hannover, Tel.: +49 511 953-60